Akkermansia muciniphila
A. muciniphila · The Mucin-Degrading Symbiont
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The human evidence rests on three small, mostly company-linked randomized trials, so a 2 (preliminary/observational moving toward early RCT) is the honest grade, not the 3 assigned. The first, Depommier and colleagues in Nature Medicine (2019), enrolled 40 overweight, insulin-resistant adults with 32 completing, and was framed by the authors themselves as a proof-of-concept exploratory study rather than a definitive efficacy trial. The pasteurized form associated with improved insulin sensitivity and lower total cholesterol, while changes in body weight and fat mass were only borderline (P around 0.09). The second, published in Cell Metabolism (2024) with 58 people who had overweight or obese type 2 diabetes, found no overall between-group effect on weight or HbA1c and only a signal in the pre-specified subgroup that started with low gut Akkermansia. The third, Mount and colleagues in Nature Medicine (May 2026), reported roughly 2 kg less weight regain during a 24-week maintenance phase after a low-energy diet, again with a larger effect in those with lower baseline levels. Independent commentators called the 2026 result an interesting proof of concept, not practice-changing, citing small samples, short follow-up, a selected population and no comparison to GLP-1 medicines. Both A-Mansia Biotech and Pendulum, the two commercial developers, are founded or advised by the trial investigators, so brand-funded and independent evidence should be read separately.
- FDA
- Legal supplement; NDI (New Dietary Ingredient) submitted
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Short-term human safety looks reassuring, but the category is young, the effect is modest, and mucin degradation makes over-colonization a genuine, context-dependent caution rather than a purely theoretical one.
Akkermansia muciniphila is a next-generation probiotic, a gut symbiont that lives in the mucus layer of the intestine and was first isolated in 2004 by Muriel Derrien and Willem de Vos at Wageningen University in the Netherlands. It draws attention because it is consistently depleted in people with obesity, type 2 diabetes, inflammatory bowel disease and fatty liver, and because a heat-killed (pasteurized) preparation appears to keep, and may even sharpen, its effects. The honest headline is that the human record is still thin: three small randomized trials, all tied to the companies that sell it, showing modest and inconsistent metabolic signals rather than a settled clinical benefit. It is sold as a live probiotic (Pendulum) and, in Europe, as a pasteurized postbiotic novel food (A-Mansia). It is not a treatment, and more Akkermansia is not automatically better.
Next-generation probiotic, the mucus-layer symbiont with metabolic-health emerging evidence.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Akkermansia muciniphila is a "next-generation" probiotic with biology unlike any of the classical Lactobacillus or Bifidobacterium probiotic strains. The organism is a gram-negative anaerobe in the Verrucomicrobia phylum, taxonomically distant from every traditional probiotic. It lives in the dense mucus layer covering the colonic epithelium rather than in the lumen, and its primary metabolic substrate is mucin: the heavily-glycosylated glycoprotein that humans secrete continuously to coat the gut lining. By degrading mucin and replenishing the mucus layer through stimulated secretion, Akkermansia maintains a constant turnover of the mucosal barrier that separates trillions of luminal microbes from the immune system. It typically comprises 1-4% of total gut microbiome composition in healthy adults, substantially more than most named probiotic species. The metabolic and immune mechanisms have driven explosive scientific interest since the 2004 discovery. Akkermansia abundance is inversely correlated with obesity, type 2 diabetes, metabolic syndrome, inflammatory bowel disease, and several cancer phenotypes, among the most robust microbiome-disease associations in the literature. The Cani laboratory at Université catholique de Louvain established the metabolic mechanism: Akkermansia outer membrane protein Amuc_1100 binds TLR2 receptors on intestinal epithelial cells, strengthening tight junctions and reducing gut barrier permeability. This reduces translocation of bacterial endotoxin (LPS) into circulation, the "metabolic endotoxemia" that drives chronic low-grade inflammation in obesity and metabolic disease. Pasteurized (heat-killed) Akkermansia retains the Amuc_1100 mechanism while improving manufacturing safety and shelf stability, the 2019 Depommier pilot trial used pasteurized form and showed metabolic improvements in obese-insulin-resistant adults. The pasteurized form received EU novel food approval in 2021 (the first such approval for a probiotic) and entered the consumer market through Pendulum (US) and A-Mansia Biotech (Belgium).
How it is taken
The standard pasteurized form dose is 10 billion cells daily, typically as a single capsule once or twice daily with meals. Pendulum Glucose Control is dosed at 1 capsule twice daily with meals; standalone Pendulum Akkermansia is 1 capsule daily. Cold-chain shipping and refrigeration are required for most commercial products. Effects on glucose metabolism and inflammatory markers accumulate over 12 weeks; expect at least a quarter before evaluating clinical change. Take with food, particularly meals containing some fiber and polyphenols, which provide substrate for the organism and may support transient survival. The pasteurized form does not establish long-term colonization in most users; benefits depend on continuous supplementation. Most clinical evidence is from 12-week protocols; longer-term efficacy and safety are still being characterized in active research.
- Pendulum Glucose Control
- 1 capsule twice daily with meals
- Pendulum Akkermansia standalone
- 1 capsule daily
- Pasteurized form
- 10 billion cells daily (clinical trial protocol)
- Storage
- Refrigeration; cold-chain shipping
- Time to effect
- 12 weeks minimum; metabolic markers
- Diet integration
- Polyphenol-rich foods support the population
- With food
- Meals containing fiber and polyphenols ideal
- Trial commitment
- At least 3 months for evaluation
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Pendulum® Glucose Control (Akkermansia + Anaerobutyricum + Clostridium butyricum + Bifidobacterium)
The dominant US consumer product. Multi-strain formulation built around Akkermansia muciniphila plus three other beneficial anaerobes. Refrigerated; ships cold-chain. Founded by Stanford-trained researchers including Colleen Cutcliffe. Marketed primarily for blood glucose management in pre-diabetes and type 2 diabetes contexts. FDA medical food designation.
Pendulum® Akkermansia (Standalone)
Single-strain Akkermansia muciniphila product from Pendulum, for users wanting the specific organism without the additional bacterial components of Glucose Control. Live pasteurized form; refrigerated.
A-Mansia Biotech / Akkermansia muciniphila Pasteurized
Belgian academic spin-off from the Patrice Cani laboratory at Université catholique de Louvain. Produces the pasteurized form (heat-killed) used in the Depommier 2019 pilot trial and subsequent European clinical studies. Distinct commercial pathway from Pendulum; same organism, different processing focus.
Generic "Akkermansia muciniphila" Products
A handful of supplement brands have launched generic Akkermansia products without the Pendulum, A-Mansia, or established clinical sourcing. Strain identity, viability, and consistency are unverifiable. Given the organism's strict anaerobic biology and processing requirements, generic products are particularly risky for actually containing viable organism.
Stool Tests Showing Akkermansia Abundance
Not a supplement form but relevant context. Gut microbiome sequencing tests (Viome, ZOE, others) measure Akkermansia abundance, typically reported as percentage of total gut bacteria. Useful for identifying users with low baseline who may benefit most from supplementation. Most healthy adults already have 1-4% Akkermansia.
Polyphenol-Rich Diet (Endogenous Akkermansia Support)
Dietary polyphenols, particularly from pomegranate, cranberry, grape skin, green tea catechins, and berries, selectively support endogenous Akkermansia populations. Roopchand 2015 and subsequent work established the polyphenol-Akkermansia pathway. Dietary support is mechanistically meaningful alongside or instead of direct supplementation.
Pasteurized vs Live Akkermansia
The pasteurized form is functionally as effective or more effective than live Akkermansia in published trials, Plovier 2017 mechanism work showed the Amuc_1100 protein retains TLR2 binding after heat treatment. Pasteurized form has substantially better safety profile, manufacturing tolerance, and shelf life. Most modern commercial products use pasteurized form.
Who it works for, and who it does not
Type 2 diabetes / insulin resistance
The signature emerging use case. Depommier 2019 pilot trial in obese-insulin-resistant adults showed meaningful improvements in insulin sensitivity, cholesterol, and inflammation markers. Pendulum Glucose Control has emerging FDA medical food evidence. Effect sizes smaller than metformin or lifestyle intervention but additive in some protocols.
Metabolic syndrome / pre-diabetes
Extension of T2D evidence to pre-diabetic populations. Mechanism (reduced metabolic endotoxemia, improved gut barrier) is generalizable. Earlier intervention may produce larger effect sizes than established T2D, emerging evidence supports this hypothesis.
Anti-PD-1 immunotherapy melanoma patients
Routy 2018 established the correlation between Akkermansia abundance and immunotherapy response. Mechanistic interpretation: supplementation could improve outcomes. BUT, supplementation during active oncology is complicated; coordinate with oncology rather than self-supplementing.
Healthy adults for general wellness
The mass-market consumer use case. Healthy adults typically already have 1-4% Akkermansia in their microbiome, supplementation may produce smaller effects than in deficient populations. Polyphenol-rich diet may provide similar benefits at meaningfully lower cost.
Inflammatory bowel disease (UC, Crohn's)
IBD patients typically show low Akkermansia abundance. Mechanistically plausible that supplementation could help; clinical evidence remains preliminary. Active inflammation may complicate the story, coordinate with gastroenterology rather than self-supplementing.
Severely immunocompromised users
Live bacterial probiotics carry theoretical bacteremia risk in severely immunocompromised users (advanced HIV, hematologic malignancy, neutropenia). Pasteurized form addresses this concern but limited safety data in these populations. Specialist guidance.
Active cancer (non-immunotherapy contexts)
Some preliminary concerns about Akkermansia and tumor growth in specific cancer contexts. The melanoma immunotherapy data is favorable; broader cancer contexts are unclear. Coordinate with oncology during active treatment.
Pregnancy and breastfeeding
Limited systematic safety data at supplemental doses. The organism is a normal gut commensal so endogenous exposure is universal; supplemental doses without OB-GYN guidance is not established practice.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Polyphenol-rich foods (pomegranate, cranberry, grapes, berries)
Mechanistically the most important pairing. Roopchand 2015 and subsequent work established that dietary polyphenols selectively support Akkermansia populations. Combining supplementation with polyphenol-rich diet is the comprehensive approach.
Resistant starch / fermentable fiber
Inulin, oligofructose, resistant starch, and other prebiotic fibers support broader beneficial microbiome populations. Mechanistically complementary; Pendulum products often combine Akkermansia with prebiotic components.
Metformin
Metformin modestly increases Akkermansia abundance in users, possibly part of the drug's glucose-lowering mechanism. Co-administration is mechanistically aligned; clinical combination data is emerging.
SGLT2 inhibitors / GLP-1 agonists
Modern diabetes drug classes have largely independent mechanisms. Akkermansia supplementation is a reasonable adjunct but evidence for additive benefit beyond the prescribed drugs is preliminary.
Anti-PD-1 immunotherapy
Coordinate with oncology. The Routy 2018 correlation suggests potential benefit; supplementation during active immunotherapy without oncology team coordination is not established practice.
Antibiotics
Antibiotics decimate Akkermansia populations along with other gut bacteria. Concurrent supplementation during antibiotic course is largely ineffective. Wait until after antibiotic course completion to initiate or resume.
Severely immunocompromised state
Pasteurized form addresses live-bacteria concerns but safety data in advanced immunosuppression remains limited. Specialist guidance.
Bisphosphonates / iron supplements
No documented interactions with mineral or bone supplements at typical doses.
What to look for on the label
Look for: explicit "Akkermansia muciniphila" species disclosure (not just "next-generation probiotic"); pasteurized form specification (the form with established clinical evidence and better safety profile); refrigerated/cold-chain shipping; established research foundation (Pendulum from Stanford, A-Mansia from UCLouvain); clinical trial citation on label of premium products; transparent CFU count and dosing protocol. Avoid: generic Akkermansia products without established sourcing; products at unusually low price points (the manufacturing is genuinely expensive); products without refrigeration or cold-chain requirements (suggests questionable viability); products combined with extensive proprietary blends that obscure Akkermansia dose and origin.
Safety in detail
- Pasteurized form has favorable safety profile in studied populations, Plat 2019 first human safety trial established acceptable tolerability at clinical doses.
- Mild GI upset (gas, bloating, mild stool changes) is the most common consumer-level side effect, typically dose-related and resolves with continued use.
- Live Akkermansia carries theoretical concerns about bacteremia in severely immunocompromised users, but live Akkermansia is rarely the commercial form. Most products are pasteurized.
- Cancer immunotherapy context is unique, Routy 2018 correlation is favorable for anti-PD-1 melanoma but broader cancer contexts are unclear. Coordinate with oncology during active treatment.
- Pregnancy and breastfeeding: limited systematic safety data at supplemental doses. The organism is endogenous so universal exposure is baseline; supplemental dosing without OB-GYN guidance is not established practice.
- Pediatric: very limited safety data. Most clinical evidence is in adults. Not appropriate for routine pediatric use without specialist guidance.
- Long-term safety profile is still being characterized in active research. Most trials are 3-12 months; truly long-term effects are inferred rather than directly studied.
- Drug interactions: minimal at typical doses. Antibiotic concurrent use makes supplementation ineffective; coordinate timing.
- The organism is a normal gut commensal, supplementation is restoring or supporting an existing population rather than introducing a foreign organism. This biology underlies the favorable safety framework.
What people get wrong
Often saidAkkermansia is just another Lactobacillus probiotic.
ActuallyAkkermansia is in the Verrucomicrobia phylum, taxonomically distant from every traditional Lactobacillus or Bifidobacterium probiotic. The mechanism (mucin degradation, gut barrier strengthening, metabolic endotoxemia reduction) is mechanistically distinct from any classical probiotic. This is a genuinely different category.
Often saidLive Akkermansia is dramatically better than pasteurized.
ActuallyThe opposite has emerged. Plovier 2017 mechanism work showed the Amuc_1100 protein retains TLR2 binding after heat treatment. Pasteurized form has better safety profile, better shelf life, and equal or superior efficacy in published trials. Most modern commercial products use pasteurized form for good reasons.
Often saidAkkermansia supplementation reverses obesity.
ActuallyThe 2013 Everard/Cani paper in mice showed obesity reversal. Human trials at clinically-relevant doses (10 billion cells daily) show modest improvements in metabolic markers, not weight loss or obesity reversal at the magnitude seen in mice. The marketing has at times conflated mouse and human evidence.
Often saidYou should test your microbiome before supplementing.
ActuallyReasonable but not necessary. Most healthy adults have 1-4% Akkermansia abundance and may not benefit substantially from supplementation. Users with diagnosed metabolic conditions, IBD, or low abundance on prior testing have stronger rationale.
Often saidAkkermansia treats cancer.
ActuallyThe Routy 2018 melanoma correlation is interesting and has driven research interest. It does NOT mean Akkermansia treats cancer. Supplementation during active oncology should be coordinated with the oncology team, not self-administered based on correlation studies.
Often saidPendulum Glucose Control is FDA-approved.
ActuallyFDA medical food designation is not FDA drug approval. Medical foods are a regulatory category for nutritional support of specific conditions; they do not require the same evidence standard as drug approval. The distinction matters for consumer expectations.
Often saidAkkermansia is the future of probiotics.
ActuallyIt is one of several "next-generation" probiotic candidates with biology distinct from classical Lactobacillus and Bifidobacterium strains. Other candidates (Faecalibacterium prausnitzii, Eubacterium rectale, Roseburia species) are also under active investigation. Akkermansia is the most commercially developed but not necessarily the only or best.
Who profits, and who pushes back
Mainstream endocrinology and diabetes care
Akkermansia muciniphila supplementation is not currently incorporated into mainstream type 2 diabetes treatment guidelines (ADA, EASD). The pilot evidence is encouraging but the effect sizes are smaller than metformin, GLP-1 agonists, or SGLT2 inhibitors. Reasonable patient choice with good safety profile; not a substitute for established diabetes management.
Cancer research community
The Routy 2018 correlation between Akkermansia abundance and anti-PD-1 immunotherapy response is genuinely interesting but represents a correlation in observational data. Translation to clinical supplementation protocols is preliminary; uncontrolled supplementation during active oncology treatment without team coordination is not established practice.
Consumer wellness skepticism
Pendulum Glucose Control runs $200+/month at retail. Polyphenol-rich diet (pomegranate, cranberry, berries, green tea) selectively supports endogenous Akkermansia populations at meaningfully lower cost. For users without diagnosed metabolic disease, dietary approach may provide similar benefits without the supplement cost premium.
Patrice Cani
The dominant academic voice on Akkermansia research. Career-defining laboratory work on metabolic endotoxemia and probiotic interventions. Academic foundation of A-Mansia Biotech with disclosed industry interests.
Muriel Derrien
Isolated the organism in 2004. Now researcher at Danone Nutricia Research. Foundational discovery work.
Pendulum Therapeutics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Stanford-founded biotech that produces Pendulum Glucose Control and standalone Akkermansia products. Substantial commercial interests; FDA medical food designation. Aggressive direct-to-consumer marketing.
A-Mansia Biotech
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Cani laboratory commercial spin-off. Produces pasteurized Akkermansia for European market. Disclosed industry source for European clinical-trial-equivalent material.
Colleen Cutcliffe
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Stanford-trained scientist and Pendulum co-founder. Public face of US commercial Akkermansia. Aggressive marketing voice; commercial interest disclosed.
Functional medicine and gut microbiome influencer community
Various functional medicine and microbiome-focused practitioners advocate for Akkermansia supplementation. Commercial interests vary; framing tends toward optimistic. Independent academic voices (Spector) more measured than commercial voices.
How we got here
Akkermansia muciniphila's scientific history begins in 2004 with Muriel Derrien and colleagues at Wageningen University in the Netherlands. The team was investigating mucin-degrading organisms in human stool, a class of bacteria suspected to play important roles in gut mucus turnover and barrier function. From a healthy adult stool sample, Derrien isolated and characterized a novel gram-negative anaerobe in the Verrucomicrobia phylum, at the time a poorly-characterized bacterial division. The organism was named to honor Antoon Akkermans, a Dutch microbiologist who contributed substantially to anaerobic microbiology research. The explosion of interest began in the early 2010s as gut microbiome research accelerated globally. Patrice Cani's laboratory at Université catholique de Louvain in Belgium became the dominant Akkermansia research center, publishing the 2013 Everard/Cani paper demonstrating that Akkermansia supplementation reversed diet-induced obesity in mice. Subsequent mechanistic work identified the Amuc_1100 outer membrane protein as the key effector, binding TLR2 receptors on intestinal epithelial cells to strengthen tight junctions and reduce metabolic endotoxemia. The 2017 Plovier paper formalized the pasteurized-form mechanism, opening the door to commercial development. The commercial era began rapidly after the 2019 Plat first-in-humans safety trial and the 2019 Depommier metabolic pilot. Pendulum Therapeutics launched in 2020 with Glucose Control as the flagship product, built around Akkermansia plus three other beneficial anaerobes, with FDA medical food designation. A-Mansia Biotech, the academic spin-off from the Cani laboratory, launched commercial products in Europe in parallel. The 2021 EFSA novel food approval for pasteurized Akkermansia was the first such approval for any probiotic and validated the commercial pathway. The 2018 Routy melanoma-immunotherapy correlation added a separate cancer-medicine dimension to the research program, with ongoing trials investigating supplementation as adjunct to anti-PD-1 immunotherapy. The research and commercial pace has been unusual for the probiotic category, typically a 15-20 year gap between discovery and commercial maturity, but Akkermansia compressed this to roughly a decade. The 2020s are likely to see larger pivotal trials, possible new pharmaceutical-grade products, and clearer guidance on which clinical indications justify the substantial cost premium over conventional probiotics.
- 2004Derrien isolates and characterizes the organism in Netherlands
- 2013Everard/Cani diet-induced obesity reversal in mice
- 2017Plovier Amuc_1100 mechanism characterization
- 2018Routy melanoma immunotherapy correlation
- 2019Plat first human safety trial
- 2019Depommier metabolic pilot trial
- 2020Pendulum Glucose Control launches with FDA medical food designation
- 2021EFSA novel food approval for pasteurized Akkermansia
- 2022Druart comprehensive safety review
- 2023Yoon systematic review of emerging metabolic evidence
What we do not know
- Whether the Depommier 2019 pilot trial findings will replicate at scale in larger pivotal trials currently in development.
- Whether live versus pasteurized Akkermansia produces clinically distinguishable outcomes, most evidence has shifted to pasteurized form, but head-to-head comparisons are limited.
- Whether the Routy 2018 immunotherapy correlation translates to clinical supplementation protocols, or whether confounders explain the abundance-response correlation.
- Optimal dose-response curve, most published trials cluster at 10 billion cells daily without rigorous comparative dosing studies.
- Whether baseline Akkermansia abundance testing (microbiome sequencing) should guide supplementation decisions, or whether universal supplementation produces benefit regardless of baseline.
- How polyphenol-rich diet compares head-to-head with Akkermansia supplementation for endogenous population support and metabolic endpoints.
- Whether long-term supplementation (>12 months) produces sustained benefits or whether the transient nature of supplementation requires lifelong continuation.
Legal status
Pendulum Therapeutics (US) and A-Mansia Biotech (Belgium) are the two major commercial sources globally. Pendulum Glucose Control received FDA medical food designation in 2020 and is sold direct-to-consumer in the US with cold-chain shipping. EU novel food approval (2021) for pasteurized Akkermansia opened European retail channels. The cost is substantially higher than traditional probiotic supplements, Pendulum Glucose Control runs $200+/month at retail, reflecting both the manufacturing complexity and the medical food positioning. Insurance coverage varies by indication; some HSA/FSA approval. Polyphenol-rich diet remains the alternative endogenous-support pathway at meaningfully lower cost.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Pendulum Therapeutics (San Francisco) and A-Mansia Biotech (Belgium) are the two major commercial sources, both with clinical research foundations (Stanford for Pendulum, UCLouvain for A-Mansia). The manufacturing complexity is substantial, strict anaerobic conditions, careful pasteurization protocols, cold-chain distribution, and limits the number of companies capable of producing clinically-equivalent material. Generic Akkermansia products from established supplement brands without these research foundations are unlikely to contain viable or properly-processed organism. The CFU count claims on generic products are particularly difficult to verify given the organism's anaerobic nature and processing requirements.
At a glance
- Organism type
- Gram-negative anaerobe (Verrucomicrobia phylum)
- Native abundance
- 1-4% of healthy adult gut microbiome
- Habitat
- Mucus layer overlying colonic epithelium
- Primary substrate
- Mucin (intestinal glycoproteins)
- Discovery
- Derrien 2004 (Wageningen, Netherlands)
- Mechanism (Amuc_1100)
- TLR2 binding, tight junction strengthening
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Akkermansia muciniphila. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
First human RCT: pasteurized A. muciniphila improved insulin sensitivity and lipids in a 40-person pilot; live form only mild effects
Full 2019 proof-of-concept design, doses (10^10/day), endpoints, results, and A-Mansia co-founder conflict disclosure
2026 RCT: pasteurized A. muciniphila reduced weight regain by ~2 kg over 24 weeks; independent experts call it proof of concept, not practice-changing
Science Media Centre expert reaction (Mount et al., Nature Medicine 2026)
2024 T2D RCT (N=58) found no overall effect on weight or HbA1c; benefit only in the low-baseline-Akkermansia subgroup
Discovery in 2004 by Derrien and de Vos at Wageningen; ~1-3% of flora, present in ~90% of people; phylum Verrucomicrobiota; depletion in obesity, T2D, IBD, colorectal cancer, fatty liver
Wikipedia (Akkermansia muciniphila), citing primary literature
EFSA safety opinion (July 2021) and EU novel-food authorization (2022) for pasteurized A. muciniphila, excluding pregnant and lactating women; US GRAS marketing since 2021
2025 EFSA extension: pasteurized A. muciniphila safe for adolescents from 12 years at defined doses; still no data for pregnant/lactating women
Pasteurized A. muciniphila classified as a defined postbiotic per ISAPP; heat treatment preserved and even increased efficacy
ISAPP (International Scientific Association for Probiotics and Prebiotics)
Mechanism: outer-membrane protein Amuc_1100 signals through TLR2 to reinforce tight junctions and gut barrier; heat-stable through pasteurization
Double-edged sword: in Salmonella-infected gnotobiotic mice, A. muciniphila presence worsened inflammation and cut mucin-filled goblet cells 2-3 fold
PMC (Ganesh et al., commensal A. muciniphila exacerbates gut inflammation)
Over-colonization harm: A. muciniphila administration exacerbated colitis-associated colorectal cancer in mice (more tumors, more damage, fewer goblet cells)
2025 cardiometabolic review summarizing human clinical studies, mechanisms and therapeutic outlook; frames evidence as emerging
Pendulum markets a live-strain Akkermansia consumer probiotic (delayed-release, GLP-1 positioning); attribute company claims to Pendulum
The studies that matter
Derrien isolation2004
Muriel Derrien (Wageningen, Netherlands) and colleagues isolated the organism from human feces and characterized it as a novel mucin-degrading species. The name honors Antoon Akkermans, a Dutch microbiologist. Foundational discovery.
Everard / Cani obesity reversal in mice2013
Patrice Cani's laboratory at Université catholique de Louvain demonstrated that live Akkermansia supplementation reversed diet-induced obesity, improved glucose tolerance, and reduced metabolic inflammation in mice. Among the most-cited microbiome-metabolic-disease papers.
Plovier Amuc_1100 mechanism2017
Identification of the specific outer membrane protein (Amuc_1100) that mediates Akkermansia's metabolic effects through TLR2 binding. Mechanism allowed pasteurized form development with preserved efficacy.
Plat first human safety trial2019
First human safety trial of pasteurized Akkermansia in obese-insulin-resistant adults. Established acceptable safety and dosing parameters for subsequent efficacy trials.
Depommier metabolic pilot2019
Three-month pilot RCT in overweight/obese insulin-resistant volunteers: pasteurized Akkermansia (10 billion daily) improved insulin sensitivity, plasma cholesterol, and inflammation markers versus placebo. Foundational human efficacy evidence.
Routy melanoma immunotherapy response2018
Gut microbiome characterization in melanoma patients receiving anti-PD-1 immunotherapy: Akkermansia abundance correlated with treatment response. Among the strongest microbiome-cancer-immunotherapy associations.
EFSA novel food approval2021
European Food Safety Authority approved pasteurized Akkermansia as a novel food ingredient, the first such approval for a probiotic. Established regulatory pathway for commercial development.
Druart safety and bioavailability review2022
Comprehensive safety review across animal and emerging human evidence: favorable profile in studied populations. Cancer immunotherapy interactions and immunocompromised populations remain areas of active investigation.
Yoon obesity and metabolic trials review2023
Systematic review of emerging Akkermansia metabolic evidence: consistent direction of effect across small trials but most evidence remains pilot-scale. Larger pivotal trials still pending.